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Abstract: Tumor lysis syndrome (TLS) is defined as a group of metabolic derangements that 
result from the massive and abrupt release of cellular components into the bloodstream after 
rapid lysis of tumor cells. Breakdown of released materials leads to a number of electrolyte 
abnormalities, including elevated uric acid concentrations in the blood (hyperuricemia), which 
carries potentially serious consequences. The diagnosis, prevention, and management of TLS is 
complicated by variability in definitions, differences in risk factors based on patient- and tumor-
specific characteristics, and practitioner preferences in terms of pharmaceutical m  anagement 
strategies. The best prevention and management option for a particular patient depends on the 
patient’s baseline risk for TLS development, the severity of symptoms in the event of TLS 
development, practical management considerations, and financial implications of treatment.
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Epidemiology
The incidence of tumor lysis syndrome (TLS) varies with the type of tumor, but TLS 
occurs most frequently1 in patients with hematologic malignancies such as acute 
  lymphoblastic leukemia (5%–26%), acute myelogenous leukemia (3%–17%), Burkitt’s 
lymphoma (27%), and high-grade non-Hodgkin’s lymphoma (other than Burkitt’s type; 
up to 42%).1–5 TLS is observed most commonly after the initiation of cytotoxic treat-
ments, cytolytic antibodies, and radiation therapies, but it can also occur spontaneously 
before antitumor therapy is administered.3 Malignancies with characteristics such as 
a rapid proliferative rate, a large tumor burden, and high sensitivity to chemotherapy 
increase the risk for TLS.1,2 Other patient-specific characteristics associated with 
increased risk for developing TLS include pre-existing hyperuricemia, renal dysfunc-
tion, and hypovolemia.1
Etiology and pathophysiology
The metabolic disturbances that occur with TLS are due primarily to the release of 
intracellular metabolites such as nucleic acids, proteins, peptides, phosphate, and potas-
sium during cell lysis.1,2 The release of these metabolites in large amounts overloads 
the renal system, leading to hyperkalemia, hyperphosphatemia, hypocalcemia (as a 
downstream effect of hyperphosphatemia), uremia, acidosis, and hyperuricemia.1,2
Hyperuricemia and its associated complications are the most frequently recognized 
manifestations of TLS and can lead to many other clinical consequences.2 Increases in 
serum uric acid concentrations result from the release and subsequent breakdown of 
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purine-containing nucleic acids from cells. Purine catabolism 
is a multistep process by which adenine and guanine are 
broken down and eventually excreted. The enzyme xanthine 
oxidase converts hypoxanthine to xanthine in the pathway 
for adenine catabolism; it also converts xanthine to uric acid 
in the adenine and guanine catabolism pathways. In most 
organisms, uric acid is degraded further to allantoin through 
the action of urate oxidase.6 However, in humans, apes, 
and some other primates, urate oxidase has been rendered 
n  onfunctional through mutations during evolution.6 This lack 
of functional urate oxidase leads to baseline concentrations of 
uric acid that are high, relative to those in other mammals.6 
Under normal circumstances, uric acid concentrations can be 
maintained at acceptable levels by renal excretion. H  owever, 
when excretion cannot keep up with production and the 
concentration of uric acid rises, it may become insoluble 
and form crystals. Crystallization of uric acid in the renal 
tubules can cause renal insufficiency that may progress to 
acute renal failure.1
Patient presentation
Clinical signs of TLS may include a wide range of symptoms, 
from mild (nausea, vomiting, diarrhea, lethargy, edema) 
to very serious and life threatening (cardiac dysrhythmias, 
congestive heart failure, tetany, syncope, seizure, and s  udden 
death).1,3 Although the set of metabolic abnormalities that 
constitute TLS generally has been long established, s  ystematic 
classification has been attempted only recently. In 2004, Cairo 
and Bishop3 proposed dividing the diagnosis of TLS into the 
subcategories of laboratory TLS and clinical TLS, based in 
part on earlier work by Hande and Garrow.4 The diagnosis 
of laboratory TLS is based solely on the occurrence of 
e  lectrolyte and metabolic abnormalities, whereas clinical TLS 
includes the same abnormalities, but also takes into account 
the p  hysical manifestations and consequences of active TLS. 
These Cairo–Bishop definitions, which have application to 
both pediatric and adult patients, were integrated into the latest 
guidelines for the prevention and t  reatment of TLS, which 
were published in June 2008.1
Common staging systems
Most of the complications of TLS can be avoided through 
appropriate preventive measures or readily managed if 
recognized early; otherwise, serious and fatal consequences 
may occur. Therefore, it is important for clinicians to be 
cognizant of strategies to identify patients who are at risk 
before initiating chemotherapy.1,2 A grading system3 based on 
the presence or absence of clinical and laboratory criteria has 
been developed for TLS to aid in the stratification of patients 
according to risk and to help identify appropriate prophylaxis 
and treatment for patients at risk for or with established 
TLS.1,2 Currently, this grading system is being prospectively 
evaluated in pediatric patients being treated with chemoim-
munotherapy and rasburicase for newly diagnosed advanced 
B-cell non-Hodgkin’s lymphoma (as per the Children’s 
Oncology Group Study ANHL01P1).3,7 More recently, 
a risk evaluation model has been proposed by Cairo et al that 
incorporates risk factors from prior models (eg, tumor type 
and extent and bulk of disease) as well as risk factors not 
previously addressed in earlier stratification schemes (eg, age, 
pre-existing renal dysfunction, and renal involvement).8 
Fundamental approaches to the successful prevention and 
management of TLS include awareness of potential causes, 
identification and close monitoring of patients at high risk, 
implementation and optimal use of appropriate prophylactic 
measures, vigilant monitoring of laboratory and electrolyte 
levels, watching for signs and symptoms of TLS in patients at 
risk, and initiation of more active treatments when necessary. 
Early recognition and treatment for metabolic abnormalities, 
with the help of the grading system, can usually prevent the 
severe and life-threatening consequences that may occur with 
TLS (see Table 1).1,2
Treatment
Management strategies for TLS include continuation of pre-
ventive measures (ie, hydration, allopurinol use), correction 
of fluid overload or dehydration, and treatment for electrolyte, 
laboratory, and acid-based abnormalities. Pharmacologic 
agents used to treat patients with TLS-related hyperuricemia 
include allopurinol, uricozyme, and rasburicase.
Hydration and fluid management
Vigorous hydration and diuresis are essential for the 
  prevention and management of TLS. Generally, patients are 
hydrated with approximately 3 L/m2/d of fluid (or 0.2 L/kg/d 
if the patient weighs #10 kg); urine output should be 
maintained at $100 mL/m2/h (or $3 mL/kg/h if the patient 
weighs #10 kg).3 Hydration and enhanced urine flow aid in 
the excretion of uric acid and phosphate by increasing intra-
vascular volume, renal blood flow, and glomerular   filtration 
rate. Diuretics may be used to maintain adequate urine 
output if sufficient diuresis is not achieved with intravenous 
h  ydration alone. However, the use of diuretics is contraindi-
cated in the setting of hypovolemia or obstructive uropathy. 
In the past, sodium bicarbonate was used commonly to 
alkalinize the urine to improve the solubility of uric acid and Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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promote its excretion. On the other hand, alkalinization does 
little to increase the solubility of xanthine and h  ypoxanthine. 
  Alkalinization is no longer recommended, because of 
equivocal evidence of efficacy and potential complications, 
including induction of inadvertent metabolic alkalosis and 
obstructive uropathies caused by precipitation of calcium 
phosphate and xanthine crystals in the renal tubules.1,2, 9–11
inhibition of uric acid production
Allopurinol, a potent xanthine oxidase inhibitor, blocks con-
version of the purine metabolites hypoxanthine and xanthine 
to uric acid. Allopurinol has been shown to be effective in 
reducing serum uric acid concentrations12–14 and the incidence 
of uric acid-related obstructive uropathy14 in patients who are 
at risk for developing TLS. By reducing formation of uric acid, 
allopurinol decreases the incidence of obstructive uropathy 
caused by crystallization of uric acid. Although allopurinol is 
effective in preventing de novo formation of uric acid, it does 
not reduce the amount of uric acid already present. Therefore, 
it can be used concurrently with rasburicase and should be 
initiated prophylactically 0.5–3 days before administration 
of cytotoxic therapy. Allopurinol is available in both oral and 
intravenous dosage forms. The recommended daily dose is 
300 mg (pediatric oral dose: 50–100 mg/m2 every 8 hours 
[maximum dose 300 mg/m2/d] or 10 mg/kg/d divided every 
8 hours [maximum dose 800 mg/d]; pediatric intravenous 
dose: 200–400 mg/m2/d in 1–3 divided doses [maximum dose 
600 mg/d]), but dosage adjustments must be made in patients 
with glomerular filtration rate ,50 mL/min.1,3 Allopurinol 
is well tolerated but may be associated with nausea, diar-
rhea, and rash.9 Allopurinol also may interfere with the 
metabolism of 6-mercaptopurine and azathioprine, requiring 
that these medications be   administered at reduced doses. 
Until recently, allopurinol had been the only xanthine oxidase 
inhibitor available. However in February 2009, the US Food 
and Drug Administration (FDA) approved f  ebuxostat for 
the chronic management of hyperuricemia in patients with 
gout. H  owever, no data currently exist on its efficacy in the 
management of hyperuricemia-related TLS.
enzymatic removal of uric acid
Because allopurinol is effective only in preventing further 
formation of uric acid, an alternative option for the treatment 
of hyperuricemia is to promote the breakdown of uric acid to 
a more soluble form.2 Uricozyme, a nonrecombinant prepara-
tion of urate oxidase enzyme, facilitates the c  onversion of 
uric acid to allantoin, which is 5–10 times more soluble in 
urine than uric acid is.1 Urate oxidase enzyme is not present in 
humans6 and is therefore isolated from the fungus   Aspergillus 
flavus.1 Rasburicase is a recombinant, highly purified urate 
oxidase enzyme approved in 2002 by the FDA for the initial 
management of hyperuricemia in pediatric patients with 
leukemia, lymphoma, and solid tumor malignancies who 
are receiving chemotherapy that is expected to result in TLS 
and hyperuricemia. In 2009, the indications for rasburicase 
were expanded to include adult patients with the same 
clinical scenarios as those described in children. In Europe, 
rasburicase is indicated for use in children and adults with 
hematologic malignancy.
Rasburicase has been shown to be effective and safe 
in reducing hyperuricemia in patients who are at risk 
for d  evelopment of TLS.15–17 Rasburicase is generally 
well t  olerated; in a study of 1069 patients, only 44 (4%) 
reported an adverse reaction that was judged to be related 
Table 1 TLS Risk assessment and recommended therapy
Degree of risk Tumor type Therapy recommended
High * Burkitt’s lymphoma Monitoring
* High-grade non-Hodgkin’s lymphoma Hydration
* Lymphoblastic leukemia Rasburicase
* T-cell acute leukemia
*   Acute myeloid leukemia with high white blood cell count
Moderate *   Low-grade lymphoma treated with definitive therapy Monitoring
* Multiple myeloma Hydration
*   Breast carcinoma treated with chemotherapy/hormonal therapy Allopurinol
* Small-cell lung carcinoma
* Germ-cell tumors (seminoma, ovarian)
* Neuroblastoma
Low * Hodgkin’s lymphoma Monitoring
*   Low-grade lymphoma treated with interferon Hydration +/- allopurinol
* Medulloblastoma
* Merkel’s cell carcinoma
* Adenocarcinoma of the gastrointestinal tractJournal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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to r  asburicase.23 Mild adverse events include, fever, nausea, 
vomiting, constipation, and abdominal pain. In rare 
instances, rasburicase treatment can cause serious adverse 
reactions, including anaphylaxis, hemolysis, methemoglobin-
emia, sepsis, and rash. It is contraindicated in patients with 
glucose-6-phosphate dehydrogenase (G6PD) deficiency. In 
contrast to allopurinol, rasburicase doses do not need to be 
adjusted in patients with renal impairment; therefore, it may 
be given without dose adjustment to patients with renal insuf-
ficiency. Per drug interactions, rasburicase does not interfere 
with activity of the cytochrome P450 system and should not 
alter drug metabolism by those enzymes.
Rasburicase may interfere with the accurate measurement 
of plasma uric acid concentrations because it continues to 
degrade uric acid in blood samples after they have been drawn 
from patients. Therefore, blood samples should be drawn in 
chilled heparin tubes and kept on ice, starting immediately 
after collection. All uric acid assays should be completed 
within 4 hours. The half-life of rasburicase is approximately 
16–21 hours, depending on the dose;1 after appropriate 
sample collection, uric acid concentrations should be moni-
tored closely for 3–4 days after the final dose of rasburicase 
is administered during a given course of treatment. If these 
assay procedures are not followed, uric acid assay concen-
trations may appear erroneously low, which could prompt 
premature discontinuation of rasburicase therapy with a 
consequent rebound in uric acid levels and return of the risk 
potential for TLS for the patient.
The dosage of rasburicase recommended by the FDA is 
0.2 mg/kg once daily in 50 mL of normal saline solution, 
given as an intravenous infusion over 30 minutes for up to 
5 days.1 This recommended dosage, recently modified from 
the original suggested dosage range of 0.15–0.2 mg/kg daily 
for 5 days, was based on clinical studies that led to approval 
of rasburicase for its current indication. Subsequently, data 
from several other studies have shown that rasburicase can 
be clinically effective when administered at lower doses and 
for shorter durations.1,2
Various studies have used weight-based rasburicase 
dosing with a duration that could be varied according to the 
judgment of the investigator. In a compassionate-use study 
in 1069 patients (996 patients were evaluable for efficacy, 
of which 658 were children and 338 were adults), a median 
of three doses (range 1–14 doses) of rasburicase were given 
per patient with a median treatment duration of 3 days (range 
1–12 days); 99% of patients showed a positive response to 
treatment.18 In another study in 100 adult patients with d  iffuse 
large B-cell lymphoma who were at risk for developing TLS, 
including 11 patients who presented with elevated uric acid 
concentration before chemotherapy, those who received 
rasburicase 0.2 mg/kg/d for $3 days experienced rapid and 
dramatic decreases in uric acid levels.18 In a retrospective, 
single-center study of six adults and two children with hema-
tologic malignancies and uric acid concentrations $8 mg/dL 
($473 µmol/L), patients received only a single dose of 
rasburicase of about 0.15 mg/kg based on actual weight if 
they were not obese, and based on an adjusted weight if they 
were obese.20 This single dose of rasburicase was effective 
in lowering uric acid concentrations and maintaining those 
concentrations within normal limits for the next 96 hours 
in this small study.20 Although four patients had impaired 
renal function at baseline, two of whom met criteria for TLS, 
no patient required hemodialysis.20 However, in two other 
  studies, a substantial percentage of patients (5 of 13 [38%] 
and 27 of 40 [68%]) required multiple doses of rasburicase 
to successfully treat hyperuricemia.21,22 Moreover, Wang et al 
(n = 45) found that the median number of required doses 
of rasburicase (given at a dose of 0.2 mg/kg) was three in 
children and four in adults.23 Finally, a case study on one 
obese patient suggested that a single-dose strategy based 
on ideal body weight may be as effective as one based on 
actual body weight.24
Several small studies have explored the use of fixed 
instead of weight-adjusted doses in adult and pediatric 
patients, including the use of lower than recommended 
doses and of fewer than recommended administrations. In a 
study of 11 adult patients with hematologic   malignancies, 
  McDonnell et al reported that 6 mg of rasburicase was 
effective in l  owering uric acid concentrations in 10 of 
11 patients.25 However, in one morbidly obese patient who 
weighed 259 kg, the uric acid concentration decreased only 
from 17.4 mg/dL (1030 µmol/L) to 15.4 mg/dL (911 µmol/L) 
after the first dose, and a second dose of 12 mg (0.05 mg/kg) 
was necessary to reduce the uric acid concentration to 
1.4 mg/dL (83 µmol/L).25 Similarly, Hutcherson et al reported 
that 1 of 11 patients who received a single dose of rasbu-
ricase 6 mg experienced inadequate uric acid reduction and 
required a second 6 mg dose.26 Reeves et al prospectively 
compared the efficacy of a fixed 7.5 mg dose of rasburicase 
and weight-based dosing at 0.15 mg/kg in 40 adult patients. 
N  ormalization of uric acid concentrations was achieved with 
both treatments and followed a similar time course.27 An even 
lower dose (3 mg) was studied by Trifilio et al in 43 adult 
patients; uric acid normalization was achieved after 48 hours, 
but six patients (14%) required a second dose (rasburicase 
3 mg or 1.5 mg) 24 hours after administration of the first Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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3 mg dose to resolve hyperuricemia completely.28 Lee et al 
reported rapid normalization of serum uric acid concentra-
tions as a result of single administration of a fixed dose 
of rasburicase 4.5 mg in three children (aged 4–13 years) 
with acute lymphoblastic leukemia. Weight-based doses of 
r  asburicase ranged from 0.08 to 0.26 mg/kg.29
At least some of the off-label treatment approaches 
using reduced doses or less frequent than recommended 
administration of rasburicase appeared to be motivated 
in part by the desire to minimize the substantial costs 
associated with rasburicase therapy.25–29 Based on its cur-
rent average sales price, a single 6 mg dose of rasburicase 
would cost about US$1990,29 which is much less than 
the approximately US$21,000 cost of the FDA-approved 
regimen (5 days at 0.15 mg/kg, based on an average total 
body weight of 85 kg). Further investigation is warranted 
to determine the efficacy of single-dose rasburicase for the 
prevention or treatment of hyperuricemia associated with 
TLS. However, because the cost of extended hospitaliza-
tion and of hemodialysis in patients with hematologic 
malignancies who develop renal impairment have been 
shown to total up to US$52,000 (2002),30 even adminis-
tration of the full course of rasburicase in appropriately 
selected patients may result in substantial cost savings. In 
the interim, expert practice requires administration of the 
number of doses necessary to maintain plasma uric acid 
concentration within a clinically acceptable range. Actual 
values are not defined in the guidelines.1
The development of rasburicase may have reduced the 
incidence and severity of TLS and its associated complica-
tions in patients receiving cytolytic therapy for hematologic 
malignancies. However, no data on outcomes (eg, acute 
kidney injury, renal failure, hemodialysis, death) have been 
published since this agent was developed. Future studies 
are needed to examine clinical outcomes with the use of 
rasburicase in the prevention and treatment of hyperurice-
mia associated with TLS in adult and pediatric hematology 
and oncology patients. Pharmacoeconomic studies are also 
warranted to determine the optimal and most cost-effective 
dosing strategy for rasburicase use.
Summary
TLS is a dangerous complication of chemotherapeutic 
intervention that is most common in patients with hemato-
logic malignancies. Preventive measures should be used to 
reduce the incidence of TLS in patients who are at risk. If 
TLS-associated hyperuricemia develops despite preventive 
efforts, rasburicase treatment is an effective, well-tolerated 
method for returning uric acid concentrations to acceptable 
levels. Rasburicase has a special role in therapy for patients 
at high risk for TLS, such as those with acute lymphocytic 
leukemia and highly aggressive lymphomas, especially if the 
tumor burden is high. Administration of a reduced number or 
quantity of rasburicase, whether given as weight-based or flat 
doses, may help to prevent TLS complications without incur-
ring the cost of the recommended 5-day treatment course.
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